Translational Therapeutics

British Journal of Cancer (2005) 92, 290–293. doi:10.1038/sj.bjc.6602329 www.bjcancer.com
Published online 11 January 2005

The human papillomavirus E6 and E7 inducible oncogene, hWAPL, exhibits potential as a therapeutic target

M Kuroda1,2,3,5, T Kiyono4,5, K Oikawa1,2,3,5, K Yoshida1,3 and K Mukai1

  1. 1Department of Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo 160-8402, Japan
  2. 2CREST Research Project, Japan Science and Technology Corporation, Kawaguchi-shi, Saitama 332-0012, Japan
  3. 3Shinanomachi Research Park, Keio University, Shinjuku-ku, Tokyo 160-8582, Japan
  4. 4Division of Virology, National Cancer Center Research Institute, Chuo-ku, Tokyo 104-0045, Japan

Correspondence: Dr M Kuroda, Department of Pathology, Tokyo Medical University, 6-1-1, Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan. E-mail: kuroda@tokyo-med.ac.jp

5These authors contributed equally

Received 31 August 2004; Revised 12 October 2004; Accepted 15 October 2004; Published online 11 January 2005.

Top

Abstract

Here we show that human papillomavirus (HPV) E6 and E7 oncoproteins induce hWAPL expression. In addition, small interfering RNA (siRNA) of hWAPL suppressed the growth of tumours derived from SiHa cells in nude mice. Thus, hWAPL may be one of the effective targets of uterine cervical cancer therapy.

Keywords:

hWAPL, HPV, E6, E7, siRNA

Extra navigation

naturejobs

natureproducts